
Kathleen E. Squires, MD, discusses the most clinically relevant data on first-line therapy, switch strategies, and management of pregnant patients from the 2008 Conference on Retroviruses and Opportunistic Infections.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss new findings regarding the effects of delaying or interrupting antiretroviral therapy
- Describe new data from randomized studies comparing different boosted PIs and different NRTI backbones in first-line antiretroviral therapy
- Cite new insights regarding cardiovascular risks associated with antiretroviral therapy
- Recount new findings regarding the use of antiretroviral therapy in prevention of mother-to-child HIV transmission